Payment overview · 2025
General Payments
$878.56
37 reported records · 10 companies
Healthcare provider profile · identity verified
Stephen R Beaupre, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CRANSTON, RI · NPI 1619994217
Verified facts
What the public records show
CMS Open Payments records show Stephen R Beaupre, MD received $878.56 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.13 | 23.5% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $197.20 | 22.4% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.26 | 9.8% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $81.33 | 9.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.01 | 7.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.20 | 6.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.07 | 6.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $51.19 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.25 | 5.4% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $25.92 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $878.56 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.20 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.96 | 5 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $81.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.01 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.20 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.07 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.42 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $51.19 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $31.86 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 62 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
62 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 625 | 154 |
| Omeprazole | Omeprazole | 545 | 155 |
| Alendronate Sodium | Alendronate Sodium | 507 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 124 |
| Losartan Potassium | Losartan Potassium | 371 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 85 |
| Ezetimibe | Ezetimibe | 308 | 87 |
| Alprazolam | Alprazolam | 271 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 59 |
| Furosemide | Furosemide | 219 | 65 |
| Lisinopril | Lisinopril | 211 | 51 |
| Metformin Hcl | Metformin Hcl | 194 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 46 |
| Lovastatin | Lovastatin | 174 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 173 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 35 |
| Fenofibrate | Fenofibrate,micronized | 153 | 37 |
| Allopurinol | Allopurinol | 150 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 36 |
| Gabapentin | Gabapentin | 143 | 35 |
| Sertraline Hcl | Sertraline Hcl | 140 | 32 |
| Glipizide | Glipizide | 135 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 31 |
| Simvastatin | Simvastatin | 93 | 27 |
| Atenolol | Atenolol | 91 | 23 |
| Montelukast Sodium | Montelukast Sodium | 87 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 19 |
| Ozempic | Semaglutide | 82 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 26 |
| Warfarin Sodium | Warfarin Sodium | 76 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 62 |
| Diazepam | Diazepam | 73 | 14 |
| Lorazepam | Lorazepam | 73 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 24 |
| Clonazepam | Clonazepam | 71 | 14 |
| Eliquis | Apixaban | 69 | 15 |
| Tramadol Hcl | Tramadol Hcl | 67 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 62 | 62 |
| Meloxicam | Meloxicam | 61 | 23 |
| Prednisone | Prednisone | 60 | 38 |
| Potassium Chloride | Potassium Chloride | 57 | 14 |
| Trazodone Hcl | Trazodone Hcl | 57 | 18 |
| Famotidine | Famotidine | 56 | suppressed |
| Glipizide Er | Glipizide | 56 | 11 |
| Gemfibrozil | Gemfibrozil | 55 | 12 |
| Azithromycin | Azithromycin | 52 | 42 |
| Januvia | Sitagliptin Phosphate | 52 | 13 |
| Enalapril Maleate | Enalapril Maleate | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 12 |
| Ibuprofen | Ibuprofen | 48 | 19 |
| Temazepam | Temazepam | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 13 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 30 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 32 | 21 |
| Fluconazole | Fluconazole | 32 | 20 |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $878.56 · 37 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, OPSUMIT, PAXLOVID, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VYNDAMAX, WAKIX, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error